Clinical Report: Decellularized Dermis Allografts in Venous Leg Ulcer Management

Overview

The DAVE randomized controlled trial evaluated the efficacy of decellularized dermis (DCD) allografts as an adjunct to standard care in venous leg ulcers (VLUs). The study found no significant improvement in healing rates at 12 weeks with DCD use compared to standard care alone, and the trial was terminated early due to low healing rates in both groups.

Background

Venous leg ulcers affect approximately 1% of the general population and significantly impair quality of life due to pain, mobility limitations, and frequent dressing changes. They impose a substantial financial burden on healthcare systems, accounting for up to 2% of annual healthcare budgets in Western countries. Current management includes wound care, compression therapy, and sometimes skin grafting to accelerate healing. Decellularized dermis allografts, derived from cadaveric skin, provide an immunologically inert scaffold that may facilitate wound healing without requiring general anesthesia.

Data Highlights

Key Findings

• The primary outcome of healed index ulcer at 12 weeks was achieved in 5.7% of the DCD group versus 15.2% in the control group, showing no significant benefit.
• Secondary outcomes including percentage change in ulcer area, time to healing, recurrence rates, and quality of life showed no significant differences between groups.
• Five serious adverse events were attributed to the application of DCD grafts.
• The trial was terminated early due to a lower-than-expected healing rate (11.3%) across both arms, limiting statistical power.
• Baseline characteristics were similar between intervention and control groups, supporting comparability.

Clinical Implications

Decellularized dermis allografts did not demonstrate improved healing rates for venous leg ulcers when added to standard care in this trial. Clinicians should be cautious in adopting DCD grafts for VLUs until further evidence is available. The occurrence of serious adverse events suggests careful monitoring is warranted if DCD is used.

Conclusion

The DAVE trial found no evidence that decellularized dermis allografts improve healing outcomes in venous leg ulcers compared to standard care alone. Early termination and low healing rates limit definitive conclusions, highlighting the need for further research.

References

1. DAVE Trial Investigators 2023 -- Utilization of Decellularized Dermis Allografts in Managing Venous Leg Ulcers: Insights from the DAVE Randomized Controlled Trial